Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for urinary symptoms in men with benign prostatic hyperplasia and type 2 diabetes
IRCT20250401065188N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) and type 2 diabetes mellitus (T2DM) comparing Metformin + empagliflozin with Metformin + placebo (2 arms). Primary endpoint: Lower urinary tract symptoms. Started Apr 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
benign prostatic hyperplasia (BPH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20250401065188N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250401065188N1.